Methyldopa-aldomet - Template completed by: Methyldopa-MH...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Template completed by: Methyldopa-MH Aldomet® | M Dopa™ CLASS Cardiovascular agent-anti-hypertensive agent DESCRIPTION (basic summary) Methyldopa is an oral and parenteral antihypertensive agent. An analog of 3,4-dihydroxyphenylalanine (DOPA), methyldopa originally was developed to inhibit DOPA carboxylase, an enzyme critical for the biosynthesis of catecholamines MECHANISM OF ACTION After crossing the blood-brain barrier, methyldopa is decarboxylated to produce alpha- methylnorepinephrine. This metabolite stimulates central inhibitory alpha-adrenergic receptors, thereby reducing peripheral resistance and lowering blood pressure PHARMOKINETICS Methyldopa is administered orally and intravenously Methyldopa appears to cross the blood-brain barrier as well as the placenta. Antihypertensive effects last 12—24 hours. Methyldopa is eliminated biphasically, with 95% excreted during the initial phase (plasma half-life of 2 hours) and the rest
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 02/18/2012 for the course PAS 600 - 601 taught by Professor Garrubba during the Fall '10 term at Chatham University.

Page1 / 2

Methyldopa-aldomet - Template completed by: Methyldopa-MH...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online